February 7, 2018Open Access
Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study
Key Points
Key points are not available for this paper at this time.
Abstract
Treatment with agalsidase beta at higher dose compared with agalsidase alfa does not result in a difference in clinical events, which occurred especially in those with more advanced disease. A greater biochemical response, also in the presence of antibodies, and better reduction in left ventricular mass was observed with agalsidase beta.